{"filing":{"accession_number":"0001437749-26-021262","cik":"0001595248","ticker":"GNPX","company_name":"Genprex, Inc.","form":"8-K","filing_date":"2026-06-22","report_date":null,"primary_document":"gnpx20260619_8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1595248/000143774926021262/gnpx20260619_8k.htm"},"events":[{"id":12649,"run_id":11221,"accession_number":"0001437749-26-021262","anchor_item_number":"8.01","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"summary":"Genprex announced a Canadian patent allowance for Reqorsa® in combination with PD-1/PD-L1 antibodies for lung cancer treatment, expanding its intellectual property portfolio across multiple jurisdictions. While patent issuances are typically routine, this disclosure emphasizes the strategic importance of IP protection for the Acclaim-3 clinical trial and the company's competitive positioning in oncology, making it a material operational/strategic milestone rather than a routine administrative matter.","company_name":"Genprex, Inc.","ticker":"GNPX","filing_date":"2026-06-22","form":"8-K","submitted_at":null,"items":[{"id":9556,"accession_number":"0001437749-26-021262","item_number":"8.01","item_title":"Other Events.","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"Genprex announced a Canadian patent allowance for Reqorsa® in combination with PD-1/PD-L1 antibodies for lung cancer treatment, expanding its intellectual property portfolio across multiple jurisdictions. While patent issuances are typically routine, this disclosure emphasizes the strategic importance of IP protection for the Acclaim-3 clinical trial and the company's competitive positioning in oncology, making it a material operational/strategic milestone rather than a routine administrative matter.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-06-22T15:29:48.829130+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":9556,"accession_number":"0001437749-26-021262","item_number":"8.01","item_title":"Other Events.","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"Genprex announced a Canadian patent allowance for Reqorsa® in combination with PD-1/PD-L1 antibodies for lung cancer treatment, expanding its intellectual property portfolio across multiple jurisdictions. While patent issuances are typically routine, this disclosure emphasizes the strategic importance of IP protection for the Acclaim-3 clinical trial and the company's competitive positioning in oncology, making it a material operational/strategic milestone rather than a routine administrative matter.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-06-22T15:29:48.829130+00:00","company_name":"Genprex, Inc.","ticker":"GNPX","filing_date":"2026-06-22"}]}